Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT Versus Hypofractionated Radiotherapy for Salvage of Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
NCT06205316Phase 3Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Apr 2024
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate adenocarcinoma (2 arms), sponsored by Mayo Clinic. Primary endpoint: Incidence of grade 3 or higher genitourinary (GU)/gastrointestinal (GI) radiation treatment-related adverse events at 2 years. Started Apr 2024; status: active, not recruiting.
02
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT06205316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205316.